

58. The method of claim 37, wherein administration of the antibody increases the clotting time by at least 90 percent according to a prothrombin time (PT) assay.

59. The method of claim 37, wherein administration of the antibody increases the clotting time by at least 150 percent according to a prothrombin time (PT) assay.

60. The method of claim 37, wherein administration of the antibody increases the clotting time by at least 300 percent according to a prothrombin time (PT) assay.

61. The method of claim 37, wherein the cancer cell is a pancreatic, ovarian or small lung cell carcinoma.

62. A method for detecting cancer cells that express TF, the method comprising contacting cancer cells expressing TF with a detectably-labeled antibody capable of binding native human tissue factor to form an immune complex; and detecting the immune complex as being indicative of the cancer cells that express the TF.

63. The method of claim 62, wherein the method further comprises administering an effective amount of the antibody to a mammal and detecting the cancer cells that express the TF in the mammal.

64. The method of claim 62, wherein the method further comprises isolating a biological sample from the mammal and detecting the cancer cells that express TF in the sample.

REMARKS

Consideration of this Preliminary Amendment is requested prior to examination of the above-captioned application.

Claims 1-36 have been canceled in favor of claims 37-64.

Support for new claims 37-64 can be found throughout the instant case including the drawings and claims as filed originally.

For instance, particular support for the claims can be found at pgs. 21-22, bridging paragraph, especially where use of the antibodies is taught for treating various malignancies such as those of pancreatic, ovarian, and small cell carcinoma origin. Further support can be found in Examples 9 and 10 (reporting antibody use to treat tumor growth and metastasis of human breast and colorectal cancer in nude mice).

No new matter has been added by virtue of the present Preliminary Amendment.

Early consideration and allowance of the above-captioned application are respectfully requested. Should any fee be needed to consider this submission including any papers attached herewith, the USPTO is authorized to charge our deposit account 04-1105 for such fee.

Respectfully submitted,

Date: 11 July 03



Robert L. Buchanan
Registration No. 40,927
EDWARDS & ANGELL, LLP
P. O. Box 9169
Boston, MA 02209
Tel. (617) 439-4444
Fax Nos. (617) 439-4170 / 7748
Customer No.: 21874

#340284



21874

PATENT TRADEMARK OFFICE